Back to News
Market Impact: 0.2
Arcus Biosciences (RCUS) Shares Cross Below 200 DMA
Source: Nasdaq
Market Technicals & FlowsHealthcare & Biotech
Arcus Biosciences shares fell about 6% on Friday to as low as $24.32, breaking below their 200-day moving average of $24.72. The technical breakdown is a bearish signal for RCUS but is unlikely to have material broader market impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.35
Ticker Sentiment
RCUS-0.45
More News
- Apollo in talks to buy J&J orthopedics unit for nearly $20 billion
- ‘Worrying Times’ for Bonds as 10-Year Yield Nears 5%
- Investors brace for possible rate hike at uncertain Fed meeting
- Apollo Global in talks to acquire J&J’s orthopedics unit, Bloomberg News reports
- Global Bond Selloff Pushes US 10-Year Treasury Yield Toward 5%
- European stocks heading for worst week since April as ECB hike batters risk